Elevated pressure in the eye is the most common risk factor for glaucoma, an optic neuropathy that can cause blindness and affects more than 67 million people worldwide. Elevated eye pressure in glaucoma develops due to abnormal functioning of the trabecular meshwork (TM) causing intraocular fluid to back up. Next-generation glaucoma drugs will target the finely tuned mechanisms of the TM that maintain normal intraocular pressure, as described in an article in Journal of Ocular Pharmacology and Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article, one of 25 articles in a special double issue of the Journal, is available free on the Journal of Ocular Pharmacology and Therapeutics website.

The article “Intraocular Pressure Homeostasis: Maintaining Balance in a High-Pressure Environment,” by Ted Acott and coauthors, Oregon Health & Science University, Portland, OR, describes the efficient mechanisms at work in the eye to keep intraocular pressure within an acceptable range for 92-98% of the population. Understanding these mechanisms will enable the development of drug interventions to treat the unfortunate 2-8% of people that are at risk of developing elevated eye pressure and glaucoma.

“The TM, a unique multilayered tissue that controls intraocular pressure, and its surrounding structures represent viable targets for the development of novel glaucoma therapies,” write Editor-in-Chief W. Daniel Stamer, PhD, Duke University (Durham, NC) and Guest Editor John R. Samples, MD, Professor, Rocky Vista University and Director, Western Glaucoma Foundation, Portland, OR, in the Editorial “The Trabecular Meshwork Special Issue, Inspired by the TM Study Club.”

The special double issue provides a comprehensive look at the TM and next-generation glaucoma therapies in development through a collection of editorials, original research articles, and reviews.

Included is the review article “The Role of TGF-ß2 and Bone Morphogenetic Proteins in the Trabecular Meshwork and Glaucoma,” in which Robert Wordinger, Tasneem Sharma, and Abbot Clark, University of North Texas Health Science Center, Fort Worth, describe the TGF-ß superfamily of growth factors and their role in primary open-angle glaucoma (POAG), the second leading cause of blindness worldwide.

Also of note, Nelson Winkler, Mayo Clinic College of Medicine, and Michael Fautsch, Mayo Clinic, Rochester, MN, explore the current understanding of how prostaglandin analogues, first-line treatments for glaucoma, work to reduce elevated intraocular pressure, in the review article “Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways.”

###

About the Journal

Celebrating 30 years in 2014, Journal of Ocular Pharmacology and Therapeutics is an authoritative peer-reviewed journal published ten times a year online with Open Access options and in print. It is the only multidisciplinary, peer-reviewed journal providing basic and clinical research that focuses on biopharmaceuticals that have the potential to prevent, treat, and/or diagnose ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of biopharmaceuticals for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics is the Official Journal of the Association for Ocular Pharmacology and Therapeutics. Complete tables of content and a sample issue may be viewed on the Journal of Ocular Pharmacology and Therapeutics website.

About the Publisher Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Assay and Drug Development Technologies and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide.

###

Vicki Cohn
.(JavaScript must be enabled to view this email address)
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News